CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


LevilimabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2580 UC-MSCs Wiki 0.45
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19

The objective: to study the efficacy and safety of levilimab in subjects with severe COVID-19.

NCT04397562 COVID-19 Drug: Levilimab Drug: Placebo

Primary Outcomes

Description: The proportion of deaths in each group

Measure: Mortality rate

Time: Day 60

Secondary Outcomes

Description: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care; 6. Hospitalized, not requiring supplemental oxygen; 7. Not hospitalized / discharged

Measure: 7-point Ordinal Scale

Time: Day 60

Measure: Duration of hospital stay

Time: Day 60

Measure: Rate of subjects required ICU stay

Time: Day 60

Measure: Duration of ICU Stay

Time: Day 60

Measure: Rate of subjects with COVID-19 progression to critical (respiratory failure required invasive ventilation or septic shock or multiple organ failures

Time: Day 60

Measure: Rate of subjects requiring the rescue therapy

Time: Day 60

Measure: Duration of oxygen supplementation

Time: Day 60

Measure: Rate of subjects requiring the invasive ventilation

Time: Day 60

Measure: Duration of invasive ventilation

Time: Day 60


No related HPO nodes (Using clinical trials)